dc.contributor.author | Lee, ATJ | |
dc.contributor.author | Pollack, SM | |
dc.contributor.author | Huang, P | |
dc.contributor.author | Jones, RL | |
dc.date.accessioned | 2017-04-03T09:21:48Z | |
dc.date.issued | 2017-03-01 | |
dc.identifier.citation | Current treatment options in oncology, 2017, 18 (3), pp. 19 - ? | |
dc.identifier.issn | 1527-2729 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/537 | |
dc.identifier.eissn | 1534-6277 | |
dc.identifier.doi | 10.1007/s11864-017-0457-1 | |
dc.description.abstract | Two recently reported phase III randomised control trials (RCTs) have resulted in the registration of two new systemic therapies for advanced soft tissue sarcoma. Both of these trials' designs were informed by phase II data that guided the selection of sensitive STS diagnoses, enabling the demonstration of benefit in certain subtypes. A number of other phase III trials reported in the last 18 months have seemingly fit into a recurrent pattern of failure-promising efficacy signals in earlier phase studies being lost in the survival follow-up of large, highly heterogeneous cohorts. Greater effort is needed to identify histological and molecularly defined subgroups associated with differential treatment response in order to avoid the tremendous disappointment and loss of resources associated with a failed phase III trial. Additionally, improvements in available treatment of advanced STS have underpinned a prolongation in overall survival (OS). Consequently, surrogate efficacy endpoints are of increasing importance to STS drug trials. Whilst progression-free survival (PFS) should arguably replace overall survival as the primary endpoint of choice in first-line studies, more work is required to provide definitive validation of surrogacy, as well as developing more sophisticated techniques of assessing radiological response and expanding the inclusion of quality-of-life-related endpoints. | |
dc.format | Print | |
dc.format.extent | 19 - ? | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | SPRINGER | |
dc.rights.uri | https://creativecommons.org/licenses/by/4.0 | |
dc.subject | Humans | |
dc.subject | Sarcoma | |
dc.subject | Antineoplastic Combined Chemotherapy Protocols | |
dc.subject | Neoplasm Staging | |
dc.subject | Treatment Outcome | |
dc.subject | Treatment Failure | |
dc.subject | Research Design | |
dc.subject | Randomized Controlled Trials as Topic | |
dc.subject | Clinical Trials, Phase III as Topic | |
dc.subject | Standard of Care | |
dc.title | Phase III Soft Tissue Sarcoma Trials: Success or Failure? | |
dc.type | Journal Article | |
rioxxterms.versionofrecord | 10.1007/s11864-017-0457-1 | |
rioxxterms.licenseref.uri | https://creativecommons.org/licenses/by/4.0 | |
rioxxterms.licenseref.startdate | 2017-03 | |
rioxxterms.type | Journal Article/Review | |
dc.relation.isPartOf | Current treatment options in oncology | |
pubs.issue | 3 | |
pubs.notes | No embargo | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Protein Networks | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Biology/Protein Networks | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Clinical Studies/Sarcoma Clinical Trials (R Jones)/Sarcoma Clinical Trials (R Jones) (hon.) | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Molecular Pathology/Molecular and Systems Oncology | |
pubs.organisational-group | /ICR/Primary Group/Royal Marsden Clinical Units | |
pubs.publication-status | Published | |
pubs.volume | 18 | |
pubs.embargo.terms | No embargo | |
icr.researchteam | Protein Networks | |
icr.researchteam | Sarcoma Clinical Trials (R Jones) | |
icr.researchteam | Molecular and Systems Oncology | |
dc.contributor.icrauthor | Lee, Alexander | |
dc.contributor.icrauthor | Huang, Paul | |